Ivermectin †Rx

IVM blocks Wnt/β-catenin (TOPFlash ↓, β-cat nuclear ↓), collapses Δψm (JC-1 ↓, ROS ↑), activates caspases/apoptosis. Preclinical strong in renal/breast/lung/esophageal; 3–18 mg PO (Rx) safe at antiparasitic doses—monitor neuro/CYP; emerging repurposing signals.

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

🔬⭐⭐ Preclinical — Strong in vitro and animal data; human trials limited but ongoing.IVMStromectolMectizan

Forms: Oral tablets (Rx, 3–12 mg)

Educational only, not medical advice. OncoForge makes no claim that Ivermectin †Rx treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Key Takeaway

Antiparasitic that inhibits Wnt/β-catenin signaling, disrupts mitochondrial potential/respiration, and triggers ROS-mediated apoptosis; compelling preclinical data with emerging human signals, but clinical efficacy in oncology remains to be proven.

Evidence at a glance

Tier 2 · animalRenalBreastLungEsophageal

Strong preclinical (in vitro/in vivo); human limited to phase I/II safety/signals; oncology RCTs pending.

How it may work

Ivermectin (IVM), an antiparasitic drug, inhibits the Wnt/TCF signaling pathway, reducing β-catenin nuclear translocation and downregulating genes involved in tumor growth and metastasis. It collapses mitochondrial membrane potential, inducing mitochondrial dysfunction, oxidative damage, and ROS-mediated apoptosis via caspase activation. IVM also modulates Akt/mTOR and MAPK pathways, leading to cell cycle arrest and enhanced chemotherapy sensitivity. Preclinical studies show selective toxicity to cancer cells in renal, breast, and lung models.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

Wnt/β-catenin–TCF↓Reduces nuclear translocation; downregulates Axin2/c-Myc
Mitochondrial Function↓Δψm collapse; OCR ↓, ROS ↑
Apoptosis↑Caspase activation; Akt/mTOR/MAPK modulation
Cell Cycle↓Arrest; enhances chemo sensitivity

WntMitoApoptosis

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Doxorubicin: Apoptosis boost in breast.

Overlapping mechanisms

Wnt ↓ / Mito ↓ / Apoptosis ↑: Avoid with other Wnt/mito/apoptotics; risk neuro/CYP overload.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

Neurotoxicity RiskGi Upset MildPregnancy Caution

Potential interactions

CYP3A4 inducers/inhibitors (e.g., ketoconazole)MonitorModerateTheoreticalAlters IVM levels; overdose risk.
Doxorubicin / ChemotherapyConsiderBeneficialTheoreticalApoptosis enhancement in breast.

Timing

With fatty meal: 2x absorption boost.
Cycled (e.g., 3 days on/4 off): Exploratory for oncology; reduces cumulative tox.

References

Research

No published studies for Ivermectin yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Ivermectin †Rx depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 3–18 mg (po) Antiparasitic: 0.15–0.2 mg/kg single dose. Repurposing exploratory: 12–18 mg/day (e.g., 6 mg TID) cycled. Preclinical HED from mouse (2–10 mg/kg) ~0.16–0.8 mg/kg (~11–56 mg for 70 kg); human pilots align at lower end., Doses up to 2.5mg/kg are called for in some protocols, but this is not a recognized safe dosage and could potentially be neurotoxic. Rx may be required. Single or weekly for parasites; daily cycled for oncology hypotheses. Take with fatty meal for absorption. Monitor neuro (dizziness, tremor); CYP3A4 substrates..

Trials studying Ivermectin †Rx

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Appears in these protocol claims

Ivermectin †Rx is named in these protocols discussed online. Listed for transparency: being part of a protocol is not evidence that it works, and OncoForge does not endorse them.

Ivermectin / Benzimidazole Protocol Claims : Aggressive online protocols combining ivermectin with fenbendazole or mebendazole.

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar